Clinical Trial: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Relapsed/Refractory Multiple Myeloma
Study Type: INTERVENTIONAL
Official Title: A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
Brief Summary:
This is a research study to find out if a drug called belantamab mafodotin in combination with dexamethasone, a steroid, can be safely and effectively given in the community setting.Belantamab mafodotin (BLENREP) was approved in the US in August 2020 under an FDA program called accelerated approval.In November 2022, belantamab mafodotin was removed from the market because a study to further confirm its activity in relapsed/refractory multiple myeloma did not deliver a supporting result.However, this…
Read more